Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
| 対象疾患 | Active Systemic Lupus Erythematosus |
|---|---|
| 相 | 第3相 |
| スポンサー | AstraZeneca |
| ステータス | 完了 |
| 参加者数 | 277 名 |
| 介入（薬剤） | Anifrolumab |
| 開始日 | 2021年9月13日 |
| 完了日 | 2025年4月7日 |
| 結果公開日 | 2026年5月20日 |
概要
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo
| Anifrolumab 300mg | 84 Participants |
|---|---|
| Placebo | 46 Participants |
| p-value | >0.999 |
|---|---|
| Rate difference (%) | 28.4 |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health